Chondrosarcoma

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023

Retrieved on: 
Saturday, December 9, 2023
Human, Research, PST, FN, Toxicity, Incidence, ASH, Commercial, Acute myeloid leukemia, Syndrome, Hematology, HMA, Febrile neutropenia, Patient, MRD, Science, Exposition, MDS, IDH, IDH1, Diagnosis, Chondrosarcoma, CCA, AML, Doctor of Philosophy, Cancer, Society, Mutation, ALL, Health, Pharmaceutical industry, Ivosidenib, Medicine

BOSTON, Dec. 9, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will be presenting new data in acute myeloid leukemia (AML) at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. These data provide a compelling and in-depth look into the treatment patterns and clinical outcomes observed in real-world settings, offering valuable insights for informed decision-making in patient care.

Key Points: 
  • These data provide a compelling and in-depth look into the treatment patterns and clinical outcomes observed in real-world settings, offering valuable insights for informed decision-making in patient care.
  • In the analysis of 238 patients, Tibsovo+HMA elicited a higher complete response (CR) rate versus venetoclax+HMA at 42.9% vs. 26.7% (p=0.007).
  • Median time from diagnosis to start of treatment was 14 versus 20 days for Tibsovo+HMA vs venetoclax+HMA.
  • "At Servier, we bring the patient voice into everything we do, and our commitment to patients extends far beyond approval," emphasized Becky Martin, PhD, Chief of Medical, Servier Pharmaceuticals.

Chondrosarcoma Market Outlook to 2032: Emerging Therapies and Market Access Drive Growth in the 7MM, Addressing Unmet Needs in Rare Bone Cancer Treatment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 9, 2023
Health, Oncology, TKI, EU4, Ivosidenib, Disease, Radiation, Chondrosarcoma, USD, NCCN, Patient, IDH2, IDH1, United Kingdom, Dasatinib, Drug pipeline, Pharmaceutical industry, Epidemiology

It also includes insights from key opinion leaders, pipeline activities, and market access and reimbursement scenarios for chondrosarcoma therapies.

Key Points: 
  • It also includes insights from key opinion leaders, pipeline activities, and market access and reimbursement scenarios for chondrosarcoma therapies.
  • Chondrosarcoma Cases and Market Size: As per NCCN Guidelines, nearly 65% of chondrosarcoma cases are related to IDH1 or IDH2 mutations.
  • Limited Treatment Options: Conventional chondrosarcomas, the major subtype, are considered resistant to chemotherapy and radiation, resulting in limited treatment options.
  • Market Access and Reimbursement: Reimbursement of rare disease therapies like chondrosarcoma can be limited due to high costs and lack of specific approaches to evaluating rare disease drugs.

Servier Targets Transformative Treatment of Cancer at ASCO 2023

Retrieved on: 
Thursday, May 25, 2023
Glioma, Bevacizumab, Capecitabine, INDIGO, Central European Summer Time, European Hematology Association, Survival, American Society of Clinical Oncology, Research, Acute myeloid leukemia, ASCO, MDS, AML, Azacitidine, Patient, Trifluridine/tipiracil, Cancer, EHA, IDH, IDH1, Chondrosarcoma, Safety, Society, European Commission, Cholangiocarcinoma, Dietary supplement, Nursing, Pharmaceutical industry, Laboratoires Servier

BOSTON and PARIS, May 25, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will showcase new data across its robust oncology portfolio at the American Society of Clinical Oncology (ASCO) annual meeting June 2-6, 2023. These latest data, including a plenary session selection, underscore the breadth of Servier's oncology pipeline and portfolio and the company's commitment to improving outcomes for difficult and hard-to-treat cancers with high unmet medical needs.

Key Points: 
  • These latest data, including a plenary session selection, underscore the breadth of Servier's oncology pipeline and portfolio and the company's commitment to improving outcomes for difficult and hard-to-treat cancers with high unmet medical needs.
  • Among the data to be presented is a late breaking abstract featuring the results from the Phase 3 INDIGO study of vorasidenib in patients with residual or recurrent grade 2 IDH-mutant glioma.
  • "Servier is leading the scientific research with IDH inhibition across a variety of difficult to treat cancers, and this year at ASCO, we are excited to showcase data that has the potential to shift the treatment paradigm for patients with IDH-mutant glioma," said Susan Pandya, M.D., Head of Cancer Metabolism Global Development Oncology & Immuno-Oncology, Servier.
  • Servier abstracts being presented at EHA are listed below (all times in Central European Summer Time) and are available online on the EHA website here .

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

Retrieved on: 
Wednesday, April 12, 2023
Glioma, FGFR, Differentiable function, Brownstone, Isocitrate dehydrogenase, Acute myeloid leukemia, AML, Cancer, IDH2, IDH, IDH1, Malignant transformation, Chondrosarcoma, Cholangiocarcinoma, Vaccine

Mutant IDHs (“mIDHs”) cause accumulated 2-hydroxyglutarate, leading to blockage of cell differentiation, thereby inducing malignant transformation.

Key Points: 
  • Mutant IDHs (“mIDHs”) cause accumulated 2-hydroxyglutarate, leading to blockage of cell differentiation, thereby inducing malignant transformation.
  • Thus, simultaneous inhibition on both mIDH1 and mIDH2 may be a promising strategy to overcome resistance and improve clinical efficacy.
  • HMPL-306, a dual inhibitor of mIDH1/mIDH2, developed by HUTCHMED, is being evaluated in clinical trials ( NCT04272957 , NCT04762602 , NCT04764474 ).
  • HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 9, 2023
Osteosarcoma, Sarcoma, Liver, Standard of care, Breast cancer, Skin cancer, Melanoma, GI, RP2, SCCHN, Bevacizumab, HCC, Skin, Roche, Patient, Uveal melanoma, CPS, RP1, Colorectal cancer, ORR, CSCC, Clinical trial, Epithelioid, Lung cancer, Nivolumab, RP3, SOC, Investment, CRC, Head, Radiation, Chondrosarcoma, Exercise, Hepatocellular carcinoma, Pharmaceutical industry, Medical imaging, Leiomyosarcoma

WOBURN, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2022 and provided a business update.

Key Points: 
  • Research and development expenses included $2.6 million in stock-based compensation expenses for the third quarter ended December 31, 2022.
  • S,G&A Expenses: Selling, general and administrative expenses were $11.4 million for the third quarter ended December 31, 2022, as compared to $10.3 million for the third quarter ended December 31, 2021.
  • Selling, general and administrative expenses included $4.4 million in stock-based compensation expenses for the third quarter ended December 31, 2022.
  • Net Loss: Net loss was $39.7 million for the third quarter ended December 31, 2022, as compared to a net loss of $29.7 million for the third quarter ended December 31, 2021.

Global Bone Cancer Diagnosis and Therapeutics Market Report 2022: R&D and Technological Advancements & New Product Launches to Bolster Growth - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Biotechnology, Health, Oncology, Medical Devices, News, Paget's disease, Bayer, Novartis, R, Therapy, Multiple myeloma, Diagnosis, Health, Ewing's sarcoma, Amgen, Denosumab, Growth, Patient, Transplant, Cancer, BeiGene, Pfizer, Merck & Co., Bone metastasis, Chondrosarcoma, Acquisition, Bone, Medical device, Agriculture, Pharmaceutical industry, Medical imaging, Marketing, Osteosarcoma

The "Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • However, lack of awareness in under developed nations with regards to diagnosis and therapeutics along with high cost involvement in treatment are some major factors constraints that are hindering the growth of the global bone cancer diagnosis and therapeutics market.
  • New product launches in the market are likely to drive the growth of the global bone cancer diagnosis and therapeutics market.
  • Key players of the global bone cancer diagnosis and therapeutics market are Amgen Inc., Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others.

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Retrieved on: 
Wednesday, December 7, 2022
Roche, Bristol Myers Squibb, University, Immunotherapy, Liver, Colorectal cancer, Head, Melanoma, Sarcoma, Clinical trial, CPS, CD40L, RP1, Osteosarcoma, CRC, Hepatocellular carcinoma, SCCHN, SOC, RP2, Uveal melanoma, Chondrosarcoma, Principal investigator, Skin cancer, Neck, CR, ORR, GM-CSF, Radiation, Department of Oncology, University of Cambridge, Bevacizumab, Nivolumab, Disease, Safety, Cancer, RP3, Liver disease, PR, CSCC, Patient, HCC, Medical imaging, Pharmaceutical industry, Vaccine

WOBURN, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical. The IGNYTE clinical trial is evaluating RP1 (vusolimogene oderparepvec) in combination with nivolumab, with the anti-PD1 failed melanoma cohort being conducted with registrational intent. The Company also provided new data from the ongoing Phase 1 clinical trials evaluating RP2 and RP3, as well as a detailed overview of its RP2/3 Phase 2 development plans. A virtual investor event will be held today at 8:00 a.m. ET to discuss the new data. The data from this update can be found in the presentation for today’s investor event, linked here.

Key Points: 
  • The IGNYTE clinical trial is evaluating RP1 (vusolimogene oderparepvec) in combination with nivolumab, with the anti-PD1 failed melanoma cohort being conducted with registrational intent.
  • The Company is today presenting new data from the first 75 patients from the 125 patient anti-PD1 failed melanoma cohort, which has registrational intent.
  • The IGNYTE clinical trial is being conducted under a collaboration and supply agreement with Bristol-Myers Squibb, with the anti-PD1 failed melanoma cohort expected to complete enrollment by around the end of this year.
  • This cohort was initiated after completing enrollment in a prior Phase 2 cohort in the same clinical trial of approximately 30 patients with melanoma.

AnHeart Therapeutics Receives FDA Clearance of IND Application to Initiate Global Phase 2 Study of Safusidenib in Glioma

Retrieved on: 
Thursday, December 15, 2022
Oncology, Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Therapy, III, US FDA, Drug discovery, TKI, Dana–Farber Cancer Institute, ORR, IDH1, II, IND, AXL, Patient, Entrepreneurship, Cancer, Glioma, NSCLC, IDH, FDA, ROS1, Trial of the century, Listed building, Safety, Brain, Cholangiocarcinoma, Harvard Medical School, Chondrosarcoma, Pharmaceutical industry

AnHeart Therapeutics , a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, announced today that the U.S. Food & Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to proceed with a global Phase 2 study of safusidenib for the treatment of patients with IDH1 mutant glioma.

Key Points: 
  • AnHeart Therapeutics , a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, announced today that the U.S. Food & Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to proceed with a global Phase 2 study of safusidenib for the treatment of patients with IDH1 mutant glioma.
  • Receiving IND clearance from US FDA to advance safusidenib into a global Phase 2 trial in glioma represents an important milestone, as we continue to advance our clinical pipeline of precision oncology therapeutics, said Bing Yan, M.D., Co-Founder and Global Chief Medical Officer, AnHeart Therapeutics.
  • A Phase 1 clinical trial of safusidenib in glioma patients demonstrated a promising efficacy and safety profile in 12 non-enhancing and 35 enhancing glioma patients.
  • AnHeart Therapeutics (AnHeart) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel or next-generation precision oncology therapeutics with high unmet medical needs.

TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

Retrieved on: 
Monday, November 21, 2022
COVID-19, Chondrosarcoma, United, SAN, ORR, Immunoglobulin G, Leiomyosarcoma, CD73, Oxaliplatin, Safety, Partnership, Patient, Doxorubicin, MFS, TCON, UPS, Liposarcoma, Lung cancer, Ipilimumab, Therapy, NCT, PD-L1, Sarcoma, Clinical trial, TRACON, FDA, Chinese, Fine chemical, Pharmaceutical industry

The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.

Key Points: 
  • The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
  • Dosing the first patient in a trial that studies envafolimab with YH001 in front line sarcoma patients, including in combination with standard of care doxorubicin, is an important step to inform us as to the subtypes of sarcoma which should enroll in the front line Phase 3 trial.
  • For more information on the Phase 1/2 trial of YH001 in combination with envafolimab and doxorubicin in advanced or metastatic sarcoma, please visit ClinicalTrials.gov and reference Identifier NCT05448820 .
  • The primary objective of the Phase 1 portion of the trial is to determine the recommended phase 2 dose ofYH001in combination with envafolimab and in combination with envafolimab with doxorubicin.

Inhibrx Announces Participation in Upcoming Scientific Conferences

Retrieved on: 
Thursday, October 20, 2022
SAN, Recombinant, Protein engineering, Therapy, Chondrosarcoma, Novel, Nasdaq, Degenerative disease, MD, Bristol Myers Squibb, Neutralizing antibody, Safety, Agonist, Pharmaceutical industry, Communications satellite, Chiesi Farmaceutici, Patient

SAN DIEGO, Oct. 20, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at multiple upcoming scientific conferences.

Key Points: 
  • SAN DIEGO, Oct. 20, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at multiple upcoming scientific conferences.
  • Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases.
  • Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform.
  • Inhibrx has collaborations with 2seventy bio (formerly bluebird bio), Bristol-Myers Squibb and Chiesi.